Macquarie Group
TBPH icon

Macquarie Group’s Theravance Biopharma TBPH Stock Holding History

Macquarie Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-208,783
Closed -$3.05M – 1437
2025
Q3 		$3.05M Hold
208,783
– – ﹤0.01% 1059
2025
Q2 		$2.3M Hold
208,783
– – ﹤0.01% 1180
2025
Q1 		$1.86M Hold
208,783
– – ﹤0.01% 1245
2024
Q4 		$1.97M Hold
208,783
– – ﹤0.01% 1198
2024
Q3 		$1.68M Sell
208,783
-709
-0.3% -$6.14K ﹤0.01% 1282
2024
Q2 		$1.78M Buy
209,492
+709
+0.3% +$6.4K ﹤0.01% 1265
2024
Q1 		$1.87M Hold
208,783
– – ﹤0.01% 1239
2023
Q4 		$2.35M Hold
208,783
– – ﹤0.01% 1176
2023
Q3 		$1.8M Hold
208,783
– – ﹤0.01% 1193
2023
Q2 		$2.16M Hold
208,783
– – ﹤0.01% 1166
2023
Q1 		$2.27M Hold
208,783
– – ﹤0.01% 1125
2022
Q4 		$2.34M Sell
208,783
-5,296
-2% -$55.7K ﹤0.01% 1166
2022
Q3 		$2.18M Sell
214,079
-633
-0.3% -$5.93K ﹤0.01% 1197
2022
Q2 		$1.95M Hold
214,712
– – ﹤0.01% 1306
2022
Q1 		$2.05M Hold
214,712
– – ﹤0.01% 1364
2021
Q4 		$2.37M Hold
214,712
– – ﹤0.01% 1322
2021
Q3 		$1.59M Sell
214,712
-75,546
-26% -$845K ﹤0.01% 1457
2021
Q2 		$4.21M Buy
290,258
+208,783
+256% +$3.92M ﹤0.01% 1178
2021
Q1 		$1.66M Buy
81,475
+11,417
+16% +$217K ﹤0.01% 1256
2020
Q4 		$1.25M Buy
70,058
+18,675
+36% +$335K ﹤0.01% 1250
2020
Q3 		$760K Sell
51,383
-1,854
-3% -$34.7K ﹤0.01% 1300
2020
Q2 		$1.12M Buy
+53,237
New +$1.37M ﹤0.01% 1174
2016
Q1 		– Sell
-50,000
Closed -$820K – 1588
2015
Q4 		$820K Hold
50,000
– – ﹤0.01% 1108
2015
Q3 		$550K Hold
50,000
– – ﹤0.01% 1230
2015
Q2 		$651K Hold
50,000
– – ﹤0.01% 1255
2015
Q1 		$868K Sell
50,000
-27,548
-36% -$505K ﹤0.01% 1186
2014
Q4 		$1.16M Buy
+77,548
New +$1.35M ﹤0.01% 1137

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Macquarie Group's TBPH Position: Q4 2025 in Review

Macquarie Group sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 208,783 shares — an estimated $3.05M sold.

Macquarie Group first reported a position in TBPH in Q4 2014 and held it in 27 quarters. The position peaked at $4.21M in Q2 2021. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Macquarie Group reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 208,783 Theravance Biopharma shares in Q4 2025, an estimated $3.05M.
  • Macquarie Group first reported a position in Theravance Biopharma in Q4 2014 and held it in 27 quarters.
  • Macquarie Group's Theravance Biopharma position peaked at $4.21M in Q2 2021.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.